Our Technologies

Engineering the Next Generation of Cell Therapies

Endurion Therapeutics is building a vertically integrated platform company designed to overcome the defining limitations of current cell therapies: manufacturing complexity, insufficient tumour access, and imprecise cell targeting. Our proprietary LogicGate™ architecture underpins two complementary technology platforms — each addressing a distinct barrier, and each designed to operate independently or in combination.

SequencedCAR™ eliminates the need for ex vivo cell manufacturing by generating CAR-T cells directly inside the patient through a precision two-infusion system. TissueNav™ applies computational genomics and directed evolution to equip cytotoxic immune cells with the molecular signatures required to infiltrate solid tumours — a challenge that has defined the limits of cell therapy to date.

Together, these platforms position Endurion not as a single-programme company, but as a clinical-stage platform with the architecture to address multiple indications, multiple cell types, and multiple modalities from a unified technology base.

PLATFORM POSITIONING STATEMENT

“One architecture. Two platforms. Designed to reach the cancers that current therapies cannot.”